Jonathan Cohen1,2, Leonisse Mounsambote3, Perrine Prier3, Emmanuelle Mathieu d'ARGENT3, Lise Selleret3, Nathalie Chabbert-Buffet3,4, Vanina Delarouziere5, Rachel Levy5, Emile Darai3,4, Jean-Marie Antoine3. 1. Department of Gynecology and Obstetrics, Endometriosis Expert Center, Tenon Hospital, Pierre et Marie Curie University, Paris, France - drcohenjonathan@gmail.com. 2. Université Pierre et Marie Curie, Paris, France - drcohenjonathan@gmail.com. 3. Department of Gynecology and Obstetrics, Endometriosis Expert Center, Tenon Hospital, Pierre et Marie Curie University, Paris, France. 4. Université Pierre et Marie Curie, Paris, France. 5. Department of Biology of Reproduction, Tenon Hospital, Pierre et Marie Curie University, Paris, France.
Abstract
BACKGROUND: There is no consensual definition of diminished ovarian reserve and the best therapeutic strategy has not yet been demonstrated. METHODS: We performed a retrospective study to evaluate outcomes following a first in-vitro fertilization/intra-cytoplasmic sperm injection (IVF/ICSI) cycle in young women with diminished ovarian reserve. Women with tubal factor, endometriosis or previous stimulation cycle were excluded. We defined diminished ovarian reserve as women ≤38 years with an AMH ≤1.1 ng/mL or antral follicular count ≤7. RESULTS: Among 59 IVF/ICSI cycles (40% IVF/60% ICSI), the pregnancy rate was 17% (10/59) and live birth rate 8.5% (5/59). Miscarriage rate was 50%. Baseline characteristics and IVF outcomes of the pregnant and not pregnant women were compared. No differences in age, antral follicular count, AMH, protocol used or number of harvested oocytes were found between the groups. A higher gonadotropin starting dose in the pregnancy group (397.5±87 IU vs. 314.8±103 IU; P=0.02) and a trend to a higher total dose received (4720±1349 IU vs. 3871±1367 IU; P=0.07) were noted. CONCLUSIONS: The present study confirms that women with diminished ovarian reserve have low live birth rates after a first IVF-ICSI cycle and that a higher gonadotropin starting dose might be associated with better outcomes.
BACKGROUND: There is no consensual definition of diminished ovarian reserve and the best therapeutic strategy has not yet been demonstrated. METHODS: We performed a retrospective study to evaluate outcomes following a first in-vitro fertilization/intra-cytoplasmic sperm injection (IVF/ICSI) cycle in young women with diminished ovarian reserve. Women with tubal factor, endometriosis or previous stimulation cycle were excluded. We defined diminished ovarian reserve as women ≤38 years with an AMH ≤1.1 ng/mL or antral follicular count ≤7. RESULTS: Among 59 IVF/ICSI cycles (40% IVF/60% ICSI), the pregnancy rate was 17% (10/59) and live birth rate 8.5% (5/59). Miscarriage rate was 50%. Baseline characteristics and IVF outcomes of the pregnant and not pregnant women were compared. No differences in age, antral follicular count, AMH, protocol used or number of harvested oocytes were found between the groups. A higher gonadotropin starting dose in the pregnancy group (397.5±87 IU vs. 314.8±103 IU; P=0.02) and a trend to a higher total dose received (4720±1349 IU vs. 3871±1367 IU; P=0.07) were noted. CONCLUSIONS: The present study confirms that women with diminished ovarian reserve have low live birth rates after a first IVF-ICSI cycle and that a higher gonadotropin starting dose might be associated with better outcomes.
Authors: Irene Woo; Lane K Christenson; Sumedha Gunewardena; Sue Ann Ingles; Semara Thomas; Ali Ahmady; Karine Chung; Kristin Bendikson; Richard Paulson; Lynda K McGinnis Journal: J Assist Reprod Genet Date: 2018-07-09 Impact factor: 3.412
Authors: Robert Sheppard Nickel; Jacqueline Y Maher; Michael H Hsieh; Meghan F Davis; Matthew M Hsieh; Lydia H Pecker Journal: J Clin Med Date: 2022-04-21 Impact factor: 4.964
Authors: Ling-Nv Yao; Wen-Qin Lin; Nan Jiang; Chuyan Li; Hai-Feng Cao; Hong Li; Jian-Hua Qian Journal: J Int Med Res Date: 2020-06 Impact factor: 1.671
Authors: Loukia Vassilopoulou; Michail Matalliotakis; Maria I Zervou; Charoula Matalliotaki; Demetrios A Spandidos; Ioannis Matalliotakis; George N Goulielmos Journal: Exp Ther Med Date: 2018-06-13 Impact factor: 2.447